nib (NHF) H2 2024 earnings summary

Executive summary

• Group revenue grew 9.3% to $3.3 billion, with net profit after tax up 67.4% to $181.6 million and underlying operating profit up 77.3% to $257.5 million, driven by strong digital adoption, expanded health services, and robust segment growth.

• Earnings and underlying profit increased despite challenging market conditions, claims inflation normalizing post-COVID, and cost of living pressures.

• New businesses (Honeysuckle Health, Midnight Health, nib Thrive) contributed to growth, though some remain cash flow negative as they scale.

• Sustainability and ESG initiatives exceeded targets, including carbon neutral status and climate action.

• CEO Mark Fitzgibbon announced retirement, with Ed Close named as successor.

Financial highlights

• Group revenue: $3.3 billion, up 9.3% year-over-year; UOP: $257.5 million, up 77.3%; NPAT: $181.6 million, up 67.4%.

• Statutory EPS was 38.3 cents for FY24, up 58.9%; full-year dividend increased to 29 cents per share, payout ratio 75.7%.

• Net investment income rose 12.8% to $61.7 million; operating cash flow up 4.2% to $257.1 million.

• Claims expense rose 6.7% to $2,487.2 million; claims paid per policy in ARHI up 5.7%.

• ROIC at 16.1%; PCA ratio at 1.94, indicating strong capital position.

Outlook and guidance

• Policyholder growth forecasted at 3% for the next year, outpacing industry growth; early FY25 ARHI net policyholder growth up 42.4% year-over-year.

• Claims inflation expected to normalize to 4%-6%, with ARHI net margin targeted at 6%-7% and gradual reversion to 8%-9% as inflation eases.

• Honeysuckle Health expected to break even in FY25, Midnight Health in FY26; Thrive on track for ~50,000 participants by end FY25.

• Continued focus on cost containment, productivity, and digital innovation.

• Travel sales and profitability expected to improve as international movement recovers.